• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

19.30 +0.47 (+2.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,351,508
Open 18.55
Bid (Size) 17.32 (100)
Ask (Size) 17.99 (100)
Prev. Close 18.83
Today's Range 18.35 - 19.33
52wk Range 12.58 - 23.77
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Today 18:00 EDT
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
May 18, 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+18.6%
+18.6%
1 Month
-4.1%
-4.1%
3 Month
-4.6%
-4.6%
6 Month
+12.5%
+12.5%
1 Year
+41.0%
+41.0%

More News

Read More
News headline image
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗
May 16, 2026
Via MarketBeat
News headline image
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 07, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗
May 05, 2026
Via The Motley Fool
Topics Regulatory Compliance
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
April 20, 2026
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
April 20, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
April 03, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
April 02, 2026
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
March 26, 2026
Via Finterra
Topics Economy Initial Public Offering
News headline image
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
March 25, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 26, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
February 19, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
February 05, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
February 02, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
January 29, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome
January 06, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 30, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗
December 10, 2025
Via The Motley Fool
News headline image
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From Denali Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 19.30
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 05/21/26 04:00 PM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.35B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap